Key clinical point : NFE2L2 and KEAP1 mutations account for 31.6% of all advanced squamous cell non-small cell lung cancer (NSCLC) cases, and these mutations are associated with worse real-world progression-free survival (PFS) after first-line therapy.
Major finding : NFE2L2 and KEAP1 mutations were detected in 31.6% of patients. Patients harboring these mutations had a shorter real-world PFS after first-line therapy (4.54 vs 6.25 months with wild-type disease; P = .0027).
Study details : The data come from a retrospective cohort study of 703 patients with advanced squamous cell NSCLC from a real-world US clinicogenomic database.
Disclosures: The study was funded by Takeda Development Center Americas, Inc. Y Wu, Y Yin, V Crossland, S Vincent, N Lineberry, and DV Faller are employees of Takeda Development Center Americas, Inc. PK Paik reported ties with various pharmaceutical companies.
Source: Wu Y et al. Survival outcomes and treatment patterns in patients with NFE2L2 and/or KEAP1 mutation-positive advanced squamous cell NSCLC using a real-world clinico-genomic database. Clin Lung Cancer. 2022 (May 10). Doi: 10.1016/j.cllc.2022.05.008